Table 3.
Plasma levels of counter-regulatory hormones (mean ± se) during the baseline and euglycemia periods and at the end of the hypoglycemic period in control subjects and patients with type 1 diabetes
| Baseline | Euglycemia | Hypoglycemia | |
|---|---|---|---|
| Nondiabetic control subjects (n = 4) | |||
| Epinephrine (pg/ml) | 28 ± 10 | 46 ± 8 | 555 ± 129a,b |
| Glucagon (pg/ml) | 61 ± 11 | 48 ± 7a | 175 ± 8c,d |
| GH (ng/ml) | <0.1 | 0.5 ± 0.4 | 9.7 ± 3.3a,b |
| Cortisol (μg/dl) | 11 ± 0.9 | 10 ± 1 | 20 ± 2a,b |
| Type 1 diabetic patients (n = 7) | |||
| Epinephrine (pg/ml) | 39 ± 8 | 43 ± 9 | 171 ± 102a,e |
| Glucagon (pg/ml) | 45 ± 7 | 37 ± 4 | 42 ± 4f |
| GH (ng/ml) | 0.7 ± 0.5 | 0.9 ± 0.5 | 9.0 ± 2.5a,b |
| Cortisol (μg/dl) | 16 ± 2 | 15 ± 1 | 19 ± 2b |
a
P < 0.05 vs. baseline.
b
P < 0.05 vs. euglycemia.
c
P < 0.01 vs. baseline.
d
P < 0.01 vs. euglycemia.
e
P < 0.05 vs. control subjects.
f
P < 0.001 vs. control subjects.